Chattem settles PPA suit
This article was originally published in The Tan Sheet
Executive Summary
Consumer products firm will pay $3 mil. settlement plus $500,000 "for certain fees and expenses" to Jennifer Villarreal, who suffered a hemorrhagic stroke "after allegedly ingesting Dexatrim containing PPA," Chattem says May 7. Case was scheduled for trial on May 19 in Brazoria County, Tex. district court. Chattem "will be fully released from any further liability in the case" and the settlement "will be fully funded" by firm's product liability insurance coverage and thus should not impact results of operations, Chattem says. Firm stopped formulating Dexatrim with PPA after researchers found a link to hemorrhagic stroke and FDA issued a voluntary recall (1"The Tan Sheet" Nov. 13, 2000, p. 6). Chattem notes there are no other trials currently scheduled involving Dexatrim...
You may also be interested in...
Weight-Loss Segment Future Uncertain With PPA Actions, Ephedra Questions
FDA actions discouraging the use of phenylpropanolamine-containing products will further accelerate the recent shift away from the OTC appetite suppressant ingredient toward ephedra supplements.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.